Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Rhabdomyolysis, lactic acidosis, and multiple organ failure during telbivudine treatment for hepatitis B: a case report and review of the literature

  • Jinxin Zheng1,
  • Minggui Deng1,
  • Xiaoliang Qiu2,
  • Zhong Chen1,
  • Duoyun Li1,
  • Xiangbin Deng1,
  • Qiwen Deng1 and
  • Zhijian Yu1Email author
Journal of Medical Case Reports201711:331

https://doi.org/10.1186/s13256-017-1498-6

Received: 21 April 2017

Accepted: 25 October 2017

Published: 27 November 2017

Abstract

Background

Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, and lactic acidosis. However, reported cases of telbivudine leading to multiple organ failure are rare. Here, we report a case of telbivudine-induced severe polymyositis, lactic acidosis, and multiple organ failure.

Case presentation

A 30-year-old Chinese man with hepatitis B virus infection received antiviral treatment with 600 mg of telbivudine daily for more than 11 months. He developed progressive weakness and myalgia, and subsequently experienced palpitations, chest tightness, lethargy, hypotension, and hypoxemia. Blood tests showed markedly elevated levels of alanine aminotransferase (955 U/L), aspartate aminotransferase (1375 U/L), blood urea nitrogen (14.9 mmol/L), creatine kinase (peak at 8050 U/L), and blood lactate (>20.0 mmol/L). His symptoms improved after continuous renal replacement therapy and short-term methylprednisolone treatment. Hyperbaric oxygen therapy, physical therapy, and rehabilitation for more than 2 months led to recovery of muscle strength to the normal range.

Conclusions

We conclude that continuous renal replacement and steroid therapies play key roles in stabilizing telbivudine-induced severe rhabdomyolysis, lactic acidosis, and multiple organ failure. Hyperbaric oxygen, physical therapy, and rehabilitation may aid in functional recovery after the acute phase of lactic acidosis and organ failure.

Keywords

Hepatitis BLactic acidosisMultiple organ failureRhabdomyolysisTelbivudine

Background

One of the most common infectious diseases in the world, chronic hepatitis B is a serious public health problem in China [1]. Pathogenesis of hepatitis B virus (HBV) is still not completely clear. Currently, the standard therapy for chronic hepatitis B is antiviral treatment with nucleoside analogs, including lamivudine, adefovir, entecavir, telbivudine, or tenofovir.

In October 2006, the L-nucleoside analog telbivudine at a dose of 600 mg/day was approved for HBV treatment. Compared to lamivudine, telbivudine showed a lower rate of drug resistance and higher rate of hepatitis B envelope antigen (HBeAg) seroconversion [2]. However, a clinical trial revealed myopathy to be an adverse effect [2]. Telbivudine therapy led to grade 3/4 creatine kinase (CK) elevation in 0.3 to 5% of patients [3], as well as accelerated muscle toxicity in patients with pre-existing muscle damage [4]. Telbivudine can also cause fatal rhabdomyolysis and lactic acidosis [5, 6].

Telbivudine-associated elevation of CK levels, myopathy, hyperlactatemia, and rhabdomyolysis have been frequently reported, whereas reports of multiple organ failure (MOF) are rare. Here, we describe a patient who was treated for 11 months with telbivudine for HBV and subsequently developed rhabdomyolysis, lactic acidosis, and MOF.

Case presentation

A 30-year-old Chinese man who had been HBeAg-positive for at least 10 years received telbivudine (Novartis Pharma AG, Basel, Switzerland) at a dosage of 600 mg once daily for 1 year before he presented to our hospital. He had no previous history of antiviral therapy. After 11 months of treatment, he complained of progressive pain and weakness in his lower extremities, poor appetite, nausea, and vomiting. Biochemical tests showed that his serum CK level had increased to 1000 U/L. Telbivudine was stopped immediately.

He was admitted to a ward with worsening symptoms. Laboratory tests were positive for hepatitis B surface antigen and HBeAg, but HBV deoxyribonucleic acid (DNA) was not detected. His serum CK level was elevated to 1220 U/L. Electromyography indicated slow nerve conduction velocity in both lower extremities. One week after admission, he developed shortness of breath, dyspnea, chest pain, malaise, and cold limbs with terminal cyanosis. The muscle strengths of his upper and lower extremities on the Medical Research Council scale were 2/5 and 1/5, respectively.

He was transferred to our intensive care unit, where he was found to have hypotension with a blood pressure of 82/43 mmHg. Oxygen saturation decreased to 80% despite nasal oxygen inhalation at a flow rate of 5 L/minute. Biochemical tests showed increased levels of alanine aminotransferase (ALT, 955 U/L), aspartate aminotransferase (AST, 1375 U/L), blood urea nitrogen (BUN, 14.9 mmol/L), serum CK (peak at 8050 U/L), and lactate dehydrogenase (LDH, 2040 U/L; Table 1). He was put on continuous mechanical ventilation. Arterial blood gas analysis revealed lactic acidosis, with a partial pressure of oxygen (PO2) of 63 mmHg, partial pressure of carbon dioxide in arterial blood (PaCO2) of 24.7 mmHg, pH of 7.275, bicarbonate (HCO3 -) of 11.6 mmol/L, and blood lactate level exceeding 20.0 mmol/L (upper limit of normal, 2.2 mmol/L).
Table 1

Major laboratory results according to days since hospital admission

Parameter

1 d

8 d

12 d

14 d

16 d

18 d

24 d

28 d

38 d

49 d

55 d

62 d

74 d

84 d

94 d

105 d

TB (umol/L)

13.9

15.1

19.1

22.5

14.9

14.8

12.3

9.9

12.5

12.0

6.7

6.6

8.6

10.9

ALT (U/L)

25.0

80.0

350.0

955.0

166.0

73.0

48.0

32.0

34.0

25.0

11.0

15.0

14.0

17.0

AST (U/L)

74.0

106.0

216.0

1375.0

217.0

136.0

29.0

25.0

27.0

28.0

33.0

25.0

22.0

20.0

19.0

21.0

ALB (g/L)

38.0

32.3

35.4

33.7

31.8

38.8

41.0

37.8

38.2

38.7

37.6

38.5

38.9

41.0

LDH (U/L)

439.0

438.0

494.0

2040.0

724.0

693.0

548.0

368.0

239.0

169.0

CK (U/L)

1220.0

1148.0

416.0

3568.0

8050.0

2440.0

124.0

73.0

56.0

54.0

84.0

136.0

94.0

189.0

95.0

187.0

CK-MB (U/L)

17.0

22.0

13.6

36.9

43.3

26.3

13.4

12.3

9.6

9.2

10.6

10.7

10.0

10.0

10.1

12.1

Lac (mmol/L)

2.2

20.0

5.1

2.1

2.3

2.2

1.7

1.5

1.4

1.4

1.7

2.2

1.2

WBC (× 109/L)

6.7

21.1

14.0

13.4

10.5

12.7

12.2

11.3

10.0

7.2

7.6

6.4

5.5

6.4

5.8

RBC (× 1012/L)

4.2

4.2

3.1

2.9

2.8

3.0

3.5

3.7

4.1

4.0

4.1

4.0

4.1

4.3

4.3

PLT (× 109/L)

210.0

329.0

48.0

48.0

46.0

82.0

185.0

182.0

217.0

187.0

 

246.0

236.0

222.0

197.0

209.0

BUN (mmol/L)

3.6

14.9

11.6

10.5

9.0

5.5

4.3

5.1

4.6

2.1

1.9

1.2

2.5

2.4

2.0

2.0

PT (seconds)

16.7

16.5

16.9

17.3

14.7

12.9

UMS (level)

4.0

2.0

3.0

3.0

3.0

3.0

2.0

3.0

3.0

3.0

4.0

4.0

4.0

5.0

5.0

5.0

LMS (level)

3.0

1.0

1.0

1.0

1.0

1.0

1.0

2.0

3.0

3.0

3.0

3.0

3.0

4.0

4.0

4.0

Normal ranges are given in parentheses as follows: ALB albumin (35–55 g/L), ALT alanine aminotransferase (5–45 U/L), AST aspartate aminotransferase (5–45 U/L), BUN blood urea nitrogen (1.7–7.1 mmol/L), CK creatine kinase (10–195 U/L), d days, LDH lactate dehydrogenase (80–285 U/L), LMS muscle strength of lower extremities (according to the Medical Research Council scale), - not detected, CK-MB cardiac creatinine phosphokinase isoenzyme (0–24 U/L), Lac lactate (0–2.2 mmol/L), PLT platelet (100–300 × 109/L), PT prothrombin time (10–14.5 seconds), RBC red blood cell (4.0–5.5 × 1012/L), TB total bilirubin (1.7–22.5 μmol/L), UMS muscle strength of upper extremities (according to the Medical Research Council scale), WBC white blood cell (4.0–10.0 × 109/L)

Continuous renal replacement therapy (CRRT) was maintained for 10 days, and methylprednisolone was initiated at 80 mg twice daily. These treatments led to improvements in his chest pain, dyspnea, and laboratory parameters (Table 1 and Fig. 1), but did not resolve his poor muscle strength. A biopsy of his left gastrocnemius muscle showed multiple nerve root inflammation and polymyositis with multiple degenerating atrophic myofibers and numerous necrotic myofibers infiltrated with macrophages (Fig. 2).
Figure 1
Fig. 1

Patient’s serum lactate and creatine kinase levels during his stay in our intensive care unit

Figure 2
Fig. 2

Muscle biopsy from left gastrocnemius muscle. Hematoxylin and eosin-stained paraffin section of muscle biopsy. Multiple degenerating atrophic myofibers (arrow) and numerous necrotic myofibers infiltrated by macrophages were observed, indicating multiple nerve root inflammation and polymyositis (original magnification, ×200)

He was transferred from our intensive care unit to our infectious disease ward. His HBV DNA was elevated at 8.48 × 104 IU/ml. Antiviral treatment with adefovir dipivoxil (10 mg once daily) was started. To improve muscle strength, he received simultaneous hyperbaric oxygen (HBO) therapy for approximately 40 days, as well as physical therapy and rehabilitation (PTR; including neuromuscular electrical stimulation therapy, comprehensive paraplegic limb training, electro-acupuncture treatment, and infrared therapy) for approximately 70 days. His muscle strength gradually improved, and his serum ALT, AST, CK, and LDH levels returned to normal. He was then discharged. Six months after discharge, his muscle strength was within the normal range. He resumed his work as a taxi driver 1 year after discharge. Relationships between primary treatment, CK levels, and muscle strength are shown in Fig. 3.
Figure 3
Fig. 3

Relationship between primary treatment, creatine kinase level, and muscle strength. CK creatine kinase, CRRT continuous renal replacement therapy (for 8 days), D 1 Day 1, GC glucocorticoid therapy (including methylprednisolone, dexamethasone, and prednisone, for 44 days), HBO hyperbaric oxygen therapy (for 40 days), LMS muscle strength of lower extremities (according to the Medical Research Council scale), PTR physical therapy and rehabilitation (for 70 days)

Discussion

A new nucleoside analog for treatment of chronic hepatitis B, telbivudine inhibits synthesis of second-strand DNA through competing with the natural substrate of DNA polymerase (reverse transcriptase) [7, 8]. In one phase II clinical trial, telbivudine monotherapy reduced serum HBV DNA and ALT levels more rapidly than lamivudine monotherapy [9]. Telbivudine is currently regarded as an efficacious, well-tolerated, and safe drug for HBV treatment [10]. Despite these advantages, there have been frequent reports of adverse effects, including elevation of CK levels, myopathy, and neuropathy, associated with telbivudine treatment, particularly when combined with pegylated interferon [11]. The GLOBE study showed that telbivudine was more frequently associated with asymptomatic hyper-CK-emia compared to lamivudine (12.9 versus 4.1%) [2]. Among patients treated with telbivudine, 12 to 14% reported fatigue and malaise, 9% reported asymptomatic hyper-CK-emia, and 0.5% reported myopathy during treatment [12].

Male sex, younger age, and HBeAg negativity were independent predictors of elevated CK levels in patients receiving telbivudine treatment in China [3]. Recently, Chen et al. found that male sex and lower baseline estimated glomerular filtration rate were significant risk factors for elevation of CK levels during telbivudine treatment [13]. In our patient, the CK level was markedly elevated (peak at 8050 U/L). Male sex may have been associated with prolonged exercise or acceleration of pre-existing muscle damage, a phenomenon that was reported previously [4].

Several studies reported telbivudine-related myopathy and neuropathy, but these side effects were typically mild and reversible [1417]. To date, reports of telbivudine-induced severe side effects, such as rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF, have been very rare. Jin et al. described a 36-year-old man who developed severe refractory lactic acidosis during telbivudine monotherapy. He fully recovered after 16 weeks of hemodialysis and glucocorticosteroid treatment [6]. Wang et al. described a patient who developed hyperlactatemia during telbivudine treatment and was successfully treated with continuous venovenous hemodiafiltration [18]. However, another patient with telbivudine-induced rhabdomyolysis developed acute renal failure and metabolic acidosis by day 18 after admission and, despite hemofiltration, died within 24 hours of developing these symptoms [5]. Table 2 lists characteristics of previously reported patients who developed severe adverse effects during telbivudine treatment. As these conditions are potentially fatal, immediate hemodialysis and glucocorticosteroid therapy are indicated.
Table 2

Literature review of patients who developed severe adverse events during telbivudine treatment

Patient number

Age (years)

Adverse effect

Liver condition

Tx time (months)

Peak CK (U/L)

Peak lactate (mmol/L)

Prognosis

Reference

1

27

Myopathy

CHB

3

3243

Resolved

[4]

2

67

Myopathy

CHB

20

4775

Resolved

[14]

3

25

Myopathy

CHB

6

1614

Resolved

[15]

4

28

Myopathy

CHB

9

788

Resolved

[16]

5

25

Myopathy

CHB

13

2992

Resolved

[16]

6

68

Myopathy

CHB

2

237

Resolved

[17]

7

35

Rhabdomyolysis, lactic acidosis

CHB

11

3683

> 12.0

Resolved

[6]

8

26

lactic acidosis

CHB

12

4151

11.3

Resolved

[18]

9

30

Rhabdomyolysis, lactic acidosis, organ failure

CHB

11

8050

> 20.0

Resolved

This paper

10

48

Rhabdomyolysis, metabolic acidosis, organ failure

Cirrhosis

9

3246

Death

[5]

CHB chronic hepatitis B, CK creatine kinase, Tx treatment, lactate mmol/L × 9.608 = mg/dL

The risk factors for telbivudine-induced rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF are still unclear. A previous study found telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage [4]. Another research found that in liver transplant recipients, telbivudine-induced polyneuropathy/myopathy maybe due to diabetes [19]. When it comes to lactic acidosis or hyperlactatemia caused by telbivudine, Jin et al. found that a case with telbivudine-induced lactic acidosis had a history of hypokalemic periodic paralysis, but the relationship between the pre-existence of myopathy and telbivudine treatment was uncertain [6]. However, like the case of another previous study, our patient also had no heavy exercise or heavy drinking, and had no history of diabetes mellitus [18]. Thus the risk factors for telbivudine-induced lactic acidosis or MOF are still ambiguous and need to be further explored. The case in this study developed severe telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF; the reason maybe that his elevated CK levels and rhabdomyolysis were not discovered in a timely manner because he received no regular reexamination. Although telbivudine was stopped, the rhabdomyolysis continue progressed and developed to lactic acidosis and MOF. So during the telbivudine treatment for HBV, except for detecting the possible risk factors associated with telbivudine-induced rhabdomyolysis or lactic acidosis, monitoring for muscular abnormalities, CK levels, and rhabdomyolysis is also very important for these cases.

Mechanisms underlying telbivudine-induced myopathy and lactic acidosis remain unclear. Whereas some studies showed that telbivudine may cause mitochondrial toxicity and dysfunction, which might lead to myopathy and lactic acidosis [20], in vitro studies indicated no effect of the drug on lactic acid production, mitochondrial DNA content, or morphology [21]. Recently, Hernández-Laín et al. identified a novel RRM2B gene variant associated with telbivudine-induced mitochondrial myopathy [22]. Therefore, the mechanism remains to be elucidated.

In this report, we describe the case of 30-year-old man with telbivudine-induced severe side effects, including rhabdomyolysis, lactic acidosis, and MOF. His condition deteriorated rapidly after admission, with shortness of breath, muscle weakness, hypotension, hypoxia, and elevated CK levels within 1 week. Several reasons may account for the severe effects. Physicians may not have paid enough attention to the elevation of CK levels and myopathy during gastroenterology follow up. Underlying causes of his worsening condition were not immediately confirmed. CRRT and immunosuppressive therapy may not have been started as early as possible. Despite delays in diagnosis and treatment, our patient improved after CRRT and methylprednisolone therapy, which played key roles in the telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF.

The role of glucocorticoid in the treatment of telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF are unclear. In this study, we found our patient’s elevated lactate level in his blood and rhabdomyolysis improved significantly after CRRT and methylprednisolone therapy. But in another study, a patient with telbivudine-induced rhabdomyolysis only received hemofiltration therapy, the patient did not receive glucocorticoid therapy, and died within 24 hours [5]. Thus, the CRRT and glucocorticoid therapy may play key roles in stabilizing telbivudine-induced severe rhabdomyolysis, lactic acidosis, and MOF. Another study found that low-dose glucocorticoid for a short period of time may help to return the blood lactate level to normal, and the current study also indicated that CRRT combined with methylprednisolone therapy help to reduce the blood lactate level to normal.

However, we found that low-dose glucocorticoid therapy could not improve the poor muscle strength of our patient [6]. HBO therapy, which is very helpful in optic neuritis [23], can be used to treat myositis [24], although there have been no reports of HBO therapy for telbivudine-induced myositis or neuritis. A biopsy confirmed multiple nerve root inflammation and polymyositis in our patient, who subsequently received HBO therapy for more than 1 month and PTR for more than 2 months. Our patient gradually recovered, indicating that these interventions may be helpful in the treatment of telbivudine-induced myositis and neuritis. To the best of our knowledge, the patient in this study was the first case which experienced myopathy, rhabdomyolysis, lactic acidosis, shock, and MOF during telbivudine treatment and be treated successfully.

Conclusions

Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, lactic acidosis, and even MOF. Risk of severe side effects is especially pronounced in younger male or highly active patients. CRRT and glucocorticoid therapy should be given as soon as possible after diagnosis, while HBO and PTR may be helpful for myositis and neuritis. Patients should be closely monitored for CK levels, myopathic symptoms, and blood lactate levels during telbivudine treatment.

Abbreviations

ALT: 

Alanine aminotransferase

AST: 

Aspartate aminotransferase

BUN: 

Blood urea nitrogen

CK: 

Creatine kinase

CRRT: 

Continuous renal replacement therapy

HBeAg: 

Hepatitis B envelope antigen

HBO: 

Hyperbaric oxygen

HBV: 

Hepatitis B virus

HCO3 -

Bicarbonate

LDH: 

Lactate dehydrogenase

MOF: 

Multiple organ failure

PaCO2

Partial pressure of carbon dioxide in arterial blood

PO2

Partial pressure of oxygen

PTR: 

Physical therapy and rehabilitation

Declarations

Acknowledgements

We thank Professor Jiming Zhang (Department of Infectious Diseases, Huashan Hospital, Fudan University) for helpful suggestions on the manuscript.

Funding

This work was supported by grants from Shenzhen Scientific Research Program of the People’s Republic of China (No. JCYJ20130402151227180, JCYJ20130402151227167).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

JZ followed this case and drafted the manuscript; MD and ZC helped for the follow up of this case; DL followed the laboratory tests and completed muscle biopsy operation. XD guided the HBO therapy, physiotherapy, and rehabilitation exercises for this case; XQ, QD, and ZY revised this paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved and consented to participate by the Ethics committee of Shenzhen Nanshan Hospital, Shenzhen University.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Infectious Diseases and Shenzhen Key Lab for Endogenous Infection, Shenzhen Nanshan Hospital, Shenzhen University, Shenzhen, China
(2)
Department of Medicine, Marshall University School of Medicine, Huntington, USA

References

  1. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J Viral Hepat. 2010;17:10–7.View ArticlePubMedGoogle Scholar
  2. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–95.View ArticlePubMedGoogle Scholar
  3. Zou XJ, Jiang XQ, Tian DY. Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine. J Viral Hepat. 2011;18:892–6.View ArticlePubMedGoogle Scholar
  4. Finsterer J, Ay L. Myotoxicity of telbivudine in pre-existing muscle damage. Virol J. 2010;7:323–5.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Dang SS, Gao N, Zhang X, Jia XL. Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis. Am J Med Sci. 2011;342:73–5.View ArticlePubMedGoogle Scholar
  6. Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: A case report and literature review. World J Gastroenterol. 2013;19:5575–80.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther. 2009;26:155–69.View ArticlePubMedGoogle Scholar
  8. Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of beta-L-thymidine and beta-L-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob Agents Chemother. 2002;46:1728–33.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–88.View ArticlePubMedGoogle Scholar
  10. Amarapurkar DN. Telbivudine: a new treatment for chronic hepatitis B. World J Gastroenterol. 2007;13:6150–5.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Fleischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787–91.View ArticlePubMedGoogle Scholar
  12. Matthews SJ. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther. 2007;29:2635–53.View ArticlePubMedGoogle Scholar
  13. Chen L, Cheng C, Chen BC, Zhao Y, Zhang JM, Wang B. Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine. Eur J Clin Pharmacol. 2016;72:235–41.View ArticlePubMedGoogle Scholar
  14. Caroleo B, Galasso O, Staltari O, et al. Muscular damage during telbivudine treatment in a chronic hepatitis B patient. Muscles Ligaments Tendons J. 2011;1:57–60.PubMedPubMed CentralGoogle Scholar
  15. Wang M, Da YW, Cai HD, Lu Y, Wu LY, Jia JP. Telbivudine myopathy in a patient with chronic hepatitis B. Int J Clin Pharm. 2012;34:422–5.View ArticlePubMedGoogle Scholar
  16. Kim EH, Park H, Lee KH, Ahn SH, Kim SM, Han KH. Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B. Clin Mol Hepatol. 2013;19:82–6.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Lee SW, Jang JH, Kim BJ. Dysphagia could be the first presenting symptom of telbivudine-induced myopathy. Intern Med J. 2013;43:1048–9.View ArticlePubMedGoogle Scholar
  18. Wang YH, Wu BQ, Liu H. Continuous venovenous hemodiafiltration for hyperlactatemia caused by telbivudine in a patient with chronic hepatitis B: A case report and update review. J Dig Dis. 2015;16:164–7.View ArticlePubMedGoogle Scholar
  19. Turan I, Yapali S, Bademkiran S, et al. Telbivudine in Liver Transplant Recipients: Renal Protection Does Not Overcome the Risk of Polyneuropathy and Myopathy. Liver Transpl. 2015;21:1066–75.View ArticlePubMedGoogle Scholar
  20. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185–95.View ArticlePubMedGoogle Scholar
  21. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12:119–29.View ArticlePubMedGoogle Scholar
  22. Hernández-Laín A, Guerrero AM, Domínguez-González C, et al. A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy. J Neurol Sci. 2015;358:481–3.View ArticlePubMedGoogle Scholar
  23. Register SD, Aaron ME, Gelly HB. Hyperbaric oxygen therapy and optic neuritis: case report and literature review. Undersea Hyperb Med. 2011;38:557–9.PubMedGoogle Scholar
  24. Pell M, Saththasivam P, Stephens PL, Mychaskiw 2nd G. Therapeutic effect of hyperbaric oxygen on inclusion body myositis. Undersea Hyperb Med. 2012;39:1111–4.PubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement